Polypeptide Antagonist Targets Na/K-ATPase Src Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating obesity fail to effectively address the underlying causes of obesity-related metabolic syndrome, particularly dysregulated adipogenesis and oxidative stress in adipose tissue, leading to persistent health issues.
Innovation Solution
Administration of a polypeptide antagonist that inhibits the Na/K-ATPase and Src complex, such as pNaKtide, which reduces lipid accumulation, adipogenesis, and inflammatory cytokines, while increasing adiponectin levels and improving insulin sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current obesity treatment methods are used, then obesity symptoms are managed, but underlying causes such as dysregulated adipogenesis and oxidative stress in adipose tissue are not effectively addressed
Solution Approach 1:
The patent converts the harmful oxidative stress response into a beneficial therapeutic mechanism by using ROS-mimetic compounds that selectively induce oxidative stress in adipose tissue, thereby activating protective pathways that reduce inflammation and improve insulin sensitivity, ultimately treating metabolic syndrome
Solution Approach 2:
The patent introduces ROS-mimetic compounds as intermediary substances that mediate between the administered drug and the target adipose tissue, these compounds generate controlled oxidative stress that triggers downstream signaling pathways leading to therapeutic effects without directly targeting the complex metabolic pathways
2Quantity of substance
If polypeptide antagonist is administered to inhibit Na/K-ATPase and Src complex, then lipid accumulation and adipogenesis are reduced, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts and targets specific key components (Na/K-ATPase and Src complex) of the complex obesity pathway, using polypeptide antagonists that specifically bind to and inhibit these discrete targets, thereby simplifying the therapeutic approach by focusing on critical control points rather than attempting to modulate the entire metabolic network
Solution Approach 2:
The patent changes the functional state of the Na/K-ATPase pump by introducing polypeptide antagonists that alter its activity parameters, specifically inhibiting its role in oxidative stress amplification and adipogenesis, thereby modifying key physiological parameters (ROS production, lipid accumulation) through targeted molecular intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide antagonist significantly attenuates adiposity, reduces visceral and subcutaneous fat, and improves metabolic profiles by targeting the Na/K-ATPase-mediated ROS amplification, thereby addressing the root causes of obesity and metabolic syndrome.
Implementation Method 1
a polypeptide that inhibits the receptor function of the Na/K-ATPase and Src complex
Implementation Method 2
targeting the Na/K-ATPase-mediated ROS amplification
Implementation Method 3
reduces lipid accumulation, adipogenesis
Implementation Method 4
manipulation of the redox state of adipocytes alters their phenotype as well as reduces total body fat stores
Data Source
AI summary
Methods for treating obesity are provided and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods for reducing adiposity and adipogenesis are also provided and make use of a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject.